Cambridge University Hospitals NHS Foundation Trust (CUH)

Cambridge University Hospitals is one of the largest and most renowned NHS Trusts in the country. In addition to delivering care through Addenbrooke’s and The Rosie Hospitals, CUH is also a leading national centre for specialist treatment, a government-designated comprehensive biomedical research centre, one of only five academic health science centres in the UK, and a university teaching hospital with a worldwide reputation. The Trust employs around 7,000 people.

In 2016 there were:

  • 730,973 out-patients attendances 
  • 62,171 Inpatient episodes
  • 5,688 Births                         

CUH has over 1,000 beds and 9,000 members of staff. We are one of the largest and best known Trusts in the country. The ‘local’ hospital for our community, delivering care through its hospitals, Addenbrooke’s and the Rosie, CUH is also a leading national centre for specialist treatment; a government designated comprehensive biomedical research centre; one of six academic health science centres in the UK – as Cambridge University Health Partners (CUHP); and a university teaching hospital with a worldwide reputation. Building on these different elements, CUH’s vision is to be one of the best academic healthcare organisations in the world. Amongst other specialties, CUH is a leading national centre for specialist treatment in organ transplantation, cancer, neurosciences, paediatrics and genetics. 

Research Excellence
The CUH is a world-leading research-focused hospital which supports and delivers leadership in translational research within the NHS, both locally and nationally. CUH continues to work strategically in partnership with other NHS organisations, universities, research charities, industry and patients and the public to provide an outstanding infrastructure that builds research capacity and supports excellence in clinical research that will benefit patients. Our strengths in biomedical science are harnessed and translated into clinical research through the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (BRC), a partnership between CUH, and the University of Cambridge. Our BRC fosters partnerships and attracts industry to the Cambridge area, focusses on areas of high disease burden and clinical need with international leading investigators, and harnesses the power of informatics to deliver health benefits.

In addition, a key strategic aim of CUH is to increase meaningful patient and public involvement in research through a dynamic partnership between health professionals and the public. CUH is keen to ensure that patients and the public are both kept informed of, and able to engage in, research activities. Our website has a page dedicated to public involvement and engagement in research (see www.cuh.org.uk/research), and includes details of how to become a member of the patient and public involvement panel. A unique opportunity for the public to participate in research is provided by the Cambridge BioResource, which now includes almost 15,000 local volunteers who have provided clinical information and samples that allow them to be invited, according to their genetic makeup, to participate in clinical research studies (see www.cambridgebioresource.org.uk). The number of patients receiving relevant health services provided by or subcontracted by CUH in 2015/16, that were recruited during that period to participate in research approved by a research ethics committee was 15,448, compared with 12,966 in 2014/15.

Performance Facts

  • In January 2017, CUH is one of the highest ranked nationally for the Trust Safety Thermometer with a score of 98.7% (in relation to new harm only) and is favourable to the national average of 97.9%. 
  • HSMR for the latest month available (November 2016) is 82.2, and is 71.2 for the 12 month period December 2015 to November 2016. Latest peer data has CUH as the lowest death rate when compared to similar Teaching Trusts outside of London. CUH also has the best rate among East of England hospitals
  • The assessment of risk of a VTE was sustained above target at 97.3% in January 2017.

Chief Executive: Roland Sinker

© 2019 — The Shelford Group

Keep up to date

Follow The Shelford Group on Twitter and our RSS Feed.

If you would like more information about the Shelford Group or to get in touch, please click here